Live Breaking News & Updates on National comprehensive cancer network guidelines

Stay informed with the latest breaking news from National comprehensive cancer network guidelines on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in National comprehensive cancer network guidelines and stay connected to the pulse of your community

Retrospective Study Shows Frontline Zanubrutinib Associated With Fewer Cardiac AEs vs Ibrutinib and Acalabrutinib in CLL/SLL

A real-world study showed zanubrutinib was linked with fewer cardiac adverse effects vs ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

United-states , Miami , Florida , National-comprehensive-cancer-network-guidelines , International-congress-on-hematologic-malignancies , International-congress , Hematologic-malignancies ,

Race Can Affect Breast Cancer Test for Predicting Chemo Benefit

21-gene recurrence score may underestimate benefit of chemotherapy for young non-Hispanic Black women with ER-positive, axillary node-negative breast cancer. 21-gene recurrence score may underestimate benefit of chemotherapy for young non-Hispanic Black women with ER-positive, axillary node-negative breast cancer.

University-of-illinois , Illinois , United-states , Chicago , Hsiao-ching-huang , University-of-illinois-college-pharmacy , Journal-of-the-national-comprehensive-cancer-network , Healthday-news , Hispanic-black , Hispanic-white , National-comprehensive-cancer , Ching-huang

Race Can Affect Breast Cancer Test for Predicting Chemo Benefit

The 21-gene recurrence score may underestimate benefit of chemotherapy for young non-Hispanic Black women with ER-positive, axillary node-negative breast cancer.

Chicago , Illinois , United-states , University-of-illinois , Hsiao-ching-huang , University-of-illinois-college-pharmacy , Journal-of-the-national-comprehensive-cancer-network , Healthday-news , Hispanic-black , Hispanic-white , National-comprehensive-cancer , Ching-huang

Revolutionizing GI Oncology Around the Globe

Eileen M. O’Reilly, MD, traveled a serendipitous journey from Ireland to the United States, where she has made her mark on transforming gastrointestinal cancer treatment.

New-york , United-states , Cornell-university , Lebanon , Memorial-sloan-kettering-cancer-center , Dublin-city , Ireland , Dublin , Lebanese , Irish , American , John-crown

Dr Lamanna on the Use of Novel Agents Following Progression in CLL

Nicole Lamanna, MD, discusses how the use of novel agents could address resistance associated with current treatment options for patients with chronic lymphocytic leukemia.

Nicole-lamanna , Hematology-oncology-division , Columbia-university , National-comprehensive-cancer-network-guidelines , Herbert-irving-comprehensive-cancer-center , Hematologic-malignancies-section , Oncology-division , National-comprehensive-cancer-network , Columbia-university-herbert-irving-comprehensive-cancer-center- , Onclive-tv , Chronic-lymphocytic-leukemia ,

AstraZeneca advances scientific leadership in hematology at ASH 2023

CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of promising early pipeline

New,...

France , United-kingdom , Boston , Massachusetts , United-states , San-diego-convention-center , California , China , Usuki , Oita , Japan , Cambridge

Fruquintinib Approval Highlights Strides Made in mCRC Armamentarium in 2023

Cathy Eng, MD, FACP, FASCO, discusses the implications of the fruquintinib approval, as well as other key clinical trial data and regulatory decisions within the colorectal cancer realm in 2023; the importance of early molecular testing in this patient population; and the continued importance of enrolling eligible patients onto clinical trials.

United-states , Tennessee , Cathy-eng , Davidh-johnson , Gastrointestinal-gi-cancer-research-program , Swog-gi-committee , National-cancer-institute , Vanderbilt-ingram-cancer-center-young-adult-cancers-initiative , National-comprehensive-cancer-network-guidelines , World-congress-on-gastrointestinal-cancer , Vanderbilt-ingram-cancer-center , Medical-oncology

Overcoming Resistance Mutations Is a Focus for Novel Therapies in R/R CLL

Nicole Lamanna, MD, discusses the challenges of resistance in patients with CLL, highlights treatment being developed for patients who progress on BTK inhibitor– or venetoclax-based regimens, and emphasizes the need for further enrollment onto clinical trials.

New-york , United-states , Nicole-lamanna , National-comprehensive-cancer-network-guidelines , Hematologic-malignancies-section , Oncology-division , Columbia-university , Herbert-irving-comprehensive-cancer , National-comprehensive-cancer-network , Columbia-university-herbert-irving-comprehensive-cancer-center , News , Chronic-lymphocytic-leukemia

Dr Crawford on the Evolving Role of Active Surveillance in Prostate Cancer

E. David Crawford, MD, discusses the evolving role of active surveillance in patients with prostate cancer.

Colorado , United-states , University-of-colorado-denver , E-david-crawford , University-of-colorado-denver-school-medicine , University-of-colorado-comprehensive-cancer-center , National-comprehensive-cancer-network-guidelines , David-crawford , Urologic-oncology , Colorado-denver-school , Colorado-comprehensive-cancer-center

Newer-Generation JAK Inhibitors Expand Myelofibrosis Treatment Paradigm

Anthony M. Hunter, MD, discusses the roles for pacritinib, momelotinib, and fedratinib in patients with myelofibrosis; treatment sequencing with newer-generation JAK inhibitors after ruxolitinib; and the importance of having several treatment options in the second-line setting and beyond.

Georgia , United-states , Emory-university , Atlanta , Anthonym-hunter , Oncology-at-emory-university-school-of-medicine , Department-of-hematology , Medical-oncology , Emory-university-school , Immediate-care-center , Winship-cancer-institute